Literature DB >> 34457906

Priceless Knowledge: Attitudes and Awareness Around Drug Pricing Among US Medical Students.

Deborah Korenstein1, Anna Kaltenboeck1, Maha Mamoor1, Susan Chimonas1.   

Abstract

High US drug costs have garnered increasing attention, with multiple proposed reforms. While physicians are key stakeholders, medical education about drug pricing is not described, and medical students' understanding and attitudes are poorly understood. To assess students' awareness of drug pricing and its determinants, the authors conducted a cross-sectional, web-based survey of US medical students. Survey items included attitudes and knowledge around drug pricing and relevant education received (e.g., importance, quantity/quality of instruction). A composite knowledge score summed correct responses to 10 knowledge items. Descriptive statistics and t tests were used to evaluate associations. Among 815 viewers of the survey invitation, 361 visited the survey and 240 completed it (view rate 44%; participation rate 77%; completion rate 87%). Most participants were white (62%), in MD programs (82%), and female (53%). Nearly all (> 99%) said it was somewhat or very important to understand factors influencing drug pricing; over 90% were interested in learning more. Among year 3-4 students (n = 108), 59% reported receiving medical school instruction on pricing; few rated the quantity as adequate (7%) or the quality as excellent (3%) or good (8%). Among 10 knowledge questions, the median correct score was 6. Fewer than half (44%) knew that prices are uncorrelated with research/development costs. Knowledge was associated with year in school (p = 0.011) but not reported instructional quality or quantity. In sum, medical students report interest in drug pricing but inadequate instruction, and their knowledge is incomplete. Enhanced education is needed to equip future doctors to advocate effectively for patients around drug prices. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40670-020-01190-x. © International Association of Medical Science Educators 2021.

Entities:  

Keywords:  Drug pricing; Medical education

Year:  2021        PMID: 34457906      PMCID: PMC8368429          DOI: 10.1007/s40670-020-01190-x

Source DB:  PubMed          Journal:  Med Sci Educ        ISSN: 2156-8650


  16 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Specialty, political affiliation, and perceived social responsibility are associated with U.S. physician reactions to health care reform legislation.

Authors:  Ryan M Antiel; Katherine M James; Jason S Egginton; Robert D Sheeler; Mark Liebow; Susan Dorr Goold; Jon C Tilburt
Journal:  J Gen Intern Med       Date:  2014-02       Impact factor: 5.128

Review 3.  The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

Authors:  Aaron S Kesselheim; Jerry Avorn; Ameet Sarpatwari
Journal:  JAMA       Date:  2016 Aug 23-30       Impact factor: 56.272

4.  Innovation in the pharmaceutical industry: New estimates of R&D costs.

Authors:  Joseph A DiMasi; Henry G Grabowski; Ronald W Hansen
Journal:  J Health Econ       Date:  2016-02-12       Impact factor: 3.883

5.  The REDCap consortium: Building an international community of software platform partners.

Authors:  Paul A Harris; Robert Taylor; Brenda L Minor; Veida Elliott; Michelle Fernandez; Lindsay O'Neal; Laura McLeod; Giovanni Delacqua; Francesco Delacqua; Jacqueline Kirby; Stephany N Duda
Journal:  J Biomed Inform       Date:  2019-05-09       Impact factor: 6.317

6.  Policy Recommendations for Public Health Plans to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.

Authors:  Hilary Daniel; Sue S Bornstein
Journal:  Ann Intern Med       Date:  2019-11-12       Impact factor: 25.391

7.  Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.

Authors:  Hiroaki Saito; Akihiko Ozaki; Toyoaki Sawano; Yuki Shimada; Tetsuya Tanimoto
Journal:  JAMA Netw Open       Date:  2019-04-05

8.  Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES).

Authors:  Gunther Eysenbach
Journal:  J Med Internet Res       Date:  2004-09-29       Impact factor: 5.428

9.  Branded prescription drug spending: a framework to evaluate policy options.

Authors:  Jeromie Ballreich; G Caleb Alexander; Mariana Socal; Taruja Karmarkar; Gerard Anderson
Journal:  J Pharm Policy Pract       Date:  2017-10-02

10.  Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.

Authors:  Kiu Tay-Teo; André Ilbawi; Suzanne R Hill
Journal:  JAMA Netw Open       Date:  2019-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.